These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

465 related articles for article (PubMed ID: 37938366)

  • 1. The role of anti-diabetic drugs in NAFLD. Have we found the Holy Grail? A narrative review.
    Zachou M; Flevari P; Nasiri-Ansari N; Varytimiadis C; Kalaitzakis E; Kassi E; Androutsakos T
    Eur J Clin Pharmacol; 2024 Jan; 80(1):127-150. PubMed ID: 37938366
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Non-Alcoholic Fatty Liver Disease Treatment in Patients with Type 2 Diabetes Mellitus; New Kids on the Block.
    Athyros VG; Polyzos SA; Kountouras J; Katsiki N; Anagnostis P; Doumas M; Mantzoros CS
    Curr Vasc Pharmacol; 2020; 18(2):172-181. PubMed ID: 30961499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of newer antidiabetic drugs on nonalcoholic fatty liver and steatohepatitis: Think out of the box!
    Ranjbar G; Mikhailidis DP; Sahebkar A
    Metabolism; 2019 Dec; 101():154001. PubMed ID: 31672448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
    Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
    Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
    [TBL] [Abstract][Full Text] [Related]  

  • 5. What Does the Future Hold for Non-Alcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis?
    Doumas M; Imprialos K; Stavropoulos K; Athyros VG
    Curr Vasc Pharmacol; 2019; 17(5):425-428. PubMed ID: 31418344
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of Agents for the Treatment of Diabetes in the Management of Nonalcoholic Fatty Liver Disease.
    Budd J; Cusi K
    Curr Diab Rep; 2020 Oct; 20(11):59. PubMed ID: 33015726
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions.
    Cusi K
    Diabetologia; 2016 Jun; 59(6):1112-20. PubMed ID: 27101131
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
    Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
    Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
    Blazina I; Selph S
    Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. SGLT2 Inhibitors as the Most Promising Influencers on the Outcome of Non-Alcoholic Fatty Liver Disease.
    Mirarchi L; Amodeo S; Citarrella R; Licata A; Soresi M; Giannitrapani L
    Int J Mol Sci; 2022 Mar; 23(7):. PubMed ID: 35409028
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-alcoholic Fatty Liver Disease and Diabetes Mellitus.
    Khneizer G; Rizvi S; Gawrieh S
    Adv Exp Med Biol; 2021; 1307():417-440. PubMed ID: 32424494
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
    Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
    Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Non-alcoholic fatty liver disease and type 2 diabetes mellitus. II. Treatment].
    Pár A; Wittmann I; Pár G
    Orv Hetil; 2022 May; 163(22):855-862. PubMed ID: 35895614
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
    Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
    Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of the effects of three kinds of glucose-lowering drugs on non-alcoholic fatty liver disease in patients with type 2 diabetes: A randomized, open-label, three-arm, active control study.
    Kinoshita T; Shimoda M; Nakashima K; Fushimi Y; Hirata Y; Tanabe A; Tatsumi F; Hirukawa H; Sanada J; Kohara K; Irie S; Kimura T; Nakamura Y; Nishioka M; Obata A; Nakanishi S; Mune T; Kaku K; Kaneto H
    J Diabetes Investig; 2020 Nov; 11(6):1612-1622. PubMed ID: 32329963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical Efficacy and Body Composition Changes with Sodium Glucose Cotransporter 2 Inhibitor/Glucagon-like Peptide-1 Antagonist Combination Therapy in Patients with Type 2 Diabetes Mellitus-associated Nonalcoholic Fatty Liver Disease.
    Ishikawa T; Terai N; Sato R; Jimbo R; Kobayashi Y; Sato T; Iwanaga A; Sano T; Yokoyama J; Honma T
    Intern Med; 2024 Sep; 63(18):2491-2497. PubMed ID: 38346734
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antidiabetic drugs and non-alcoholic fatty liver disease: A systematic review, meta-analysis and evidence map.
    Kumar J; Memon RS; Shahid I; Rizwan T; Zaman M; Menezes RG; Kumar S; Siddiqi TJ; Usman MS
    Dig Liver Dis; 2021 Jan; 53(1):44-51. PubMed ID: 32912770
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The Co-Existence of NASH and Chronic Kidney Disease Boosts Cardiovascular Risk: Are there any Common Therapeutic Options?
    Papademetriou M; Athyros VG; Geladari E; Doumas M; Tsioufis C; Papademetriou V
    Curr Vasc Pharmacol; 2018; 16(3):254-268. PubMed ID: 28676027
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Concurrent Type 2 Diabetes Mellitus and Non-Alcoholic Steatohepatitis: A Review of the Evidence.
    Yabiku K
    Front Endocrinol (Lausanne); 2021; 12():768850. PubMed ID: 34950104
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
    García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
    Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.